来自:中国糖尿病杂志 编辑:顾丽萍 张颖 顾鸣宇 严率 吴艺捷|点击数:|2015-06-17
糖尿病临床研究
[摘要] 目的 观察艾塞那肽治疗口服降糖药(OADs)治疗血糖控制欠佳T2DM患者的临床疗效及安全性。 方法 对40例OADs治疗血糖控制欠佳且BMI>23 kg/m2的T2DM患者加用艾塞那肽治疗12周,测定治疗前后相关指标;稳态模型评估胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)。结果 加用艾塞那肽治疗12周后FPG、2 hPG、HbA1c、HOMA-IR、TG较治疗后下降[FPG(8.77±1.92)vs (7.49±1.14) mmol/L;2 hPG(16.55±3.20)vs(14.69±1.50)mmol/L;HbA1c(8.91±1.37)% vs (7.94±0.90)% ;HOMA-IR(1.44±0.41)vs(1.24±0.25); TG(2.21±1.34)vs(1.59±0.51)mmol/L] (P<0.01);2 hIns及HOMA-β较治疗前增加[(6.10±0.46)vs(5.96±0.65)pmol/L;(4.01±0.32)vs (3.81±0.54)](P<0.05或P<0.01)。所有病例均无严重低血糖事件发生。 结论 使用OADs治疗欠佳的T2DM患者加用艾塞那肽可降低血糖、BMI及TG,同时改善胰岛β细胞功能和IR,且安全性较好。
[关键词]糖尿病,2型;胰升血糖素样肽-1;艾塞那肽
【Abstract】 Objective To evaluate the efficacy and safety of oral hypoglycemic drugs (OADs) in combination with exenatide in poor glycemic control patients with type 2 diabetes mellitus (T2DM). Methods 40 patients, with poor glycemic control and body mass index (BMI)>23 kg/m2 were given exenatide injection for 12 weeks. Indicators were measured before and after the treatment. Insulin resistance index (HOMA-IR) and Islet β-cell function index (HOMA-β) were calculated. Results: The levels of FPG(7.49±1.14)mmol/L, 2 hPG(14.69±1.50)mmol/L, HbA1c(7.94±0.90)% declined significantly after the treatment than before[(8.77±1.92)mmol/L, (16.55±3.24)mmol/L, (8.91±1.37)%, respectively] (all P<0.01). The level of postprandial 2 hIns (6.10±0.46)pmol/L increased significantly than before (5.96±0.65)pmol/L(P<0.05). After treatment, HOMA-β index (4.01±0.32) increased than before (3.81±0.54) (P<0.01), with HOMA-IR to descend [(1.44±0.41) vs (1.24±0.25)] (P<0.01). Body weight (87.7±10.7)kg and BMI (30.34±2.91)kg/m2 dropped to (85.0±9.8)kg and (29.41±2.59)kg/m2 (P<0.01). Also, TG declined [(2.21±1.34) vs (1.59±0.51)mmol/L] (P<0.01). No significant differences in blood pressure, lipids, liver and kidney functions were observed after the treatment (P>0.05). There was no severe hypoglycemic episode. Conclusion Exenatide injection decreased the levels of FPG, 2hPG, HbA1c, BMI and TG significantly in poor control T2DM treated with oral hypoglycemic agents with better safety. It can also significantly improve islet β cell function and decrease insulin resistance..
[Key words] Diabetes mellitus,type 2;Glucagon like peptide-1;Exenatide
版权所有:《中国糖尿病杂志》社 主管单位:中华人民共和国教育部 主办单位:北京大学
地址:北京市西城区大红罗厂街1号 邮编:100034 电话(传真):010-88505683
中国糖尿病杂志社版权所 京ICP备11029051号-1 Powered by JiuduCMS 技术支持:九度创想